Skip to main content
Top
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | NSCLC | Research article

Postoperative chemoradiotherapy is superior to postoperative chemotherapy alone in squamous cell lung cancer patients with limited N2 lymph node metastasis

Authors: Liyu Su, Mingqiu Chen, Huiyan Su, Yaqing Dai, Shaoxing Chen, Jiancheng Li

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

The aim of the present study was to assess the efficacy of postoperative chemoradiotherapy (POCRT) following surgery in non-small-cell lung cancer patients with N2 lymph node metastasis (N2-NSCLC).

Methods

The clinical data of patients with N2-NSCLC treated with POCRT or postoperative chemotherapy (pCT) alone were retrospectively collected and reviewed. The overall survival (OS) rates were analyzed utilizing the Kaplan-Meier method and compared by the log-rank test. Cox regression analysis was used to determine factors significantly associated with survival. Propensity score matching (PSM) analysis was used to compensate for differences in baseline characteristics and OS was compared after matching.

Results

Between 2004 and 2014, a total of 175 patients fulfilled the inclusion criteria, 60 of whom were treated with POCRT, while 115 were administered pCT. The 1, 3 and 5-year OS rates in the POCRT and pCT groups were 98.3 vs. 86.1%, 71.7 vs. 53.0% and 45.7 vs. 39.0%, respectively (P = 0.019). Compared with pCT, POCRT improved OS in patients with squamous cell subtype (P = 0.010), no lymphovascular invasion (P = 0.006), pN2a (P = 0.006) or total number of metastatic lymph nodes ≤7 (P = 0.016). After PSM, these survival differences between POCRT and pCT remained significant in patients with squamous cell lung cancer (P = 0.010).

Conclusions

POCRT following complete resection may be beneficial for patients with squamous cell lung cancer, particularly those with limited nodal involvement.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
2.
go back to reference Didkowska J, Wojciechowska U, Manczuk M, Lobaszewski J. Lung cancer epidemiology: contemporary and future challenges worldwide. Ann Transl Med. 2016;4:150.CrossRef Didkowska J, Wojciechowska U, Manczuk M, Lobaszewski J. Lung cancer epidemiology: contemporary and future challenges worldwide. Ann Transl Med. 2016;4:150.CrossRef
3.
go back to reference Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao MS, Wistuba I, Panel WHO. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10:1243–60.CrossRef Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao MS, Wistuba I, Panel WHO. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10:1243–60.CrossRef
5.
go back to reference Robinson CG, Patel AP, Bradley JD, DeWees T, Waqar SN, Morgensztern D, Baggstrom MQ, Govindan R, Bell JM, Guthrie TJ. Postoperative radiotherapy for pathologic N2 non–small-cell lung cancer treated with adjuvant chemotherapy: A review of the National Cancer Data Base. J Clin Oncol. 2015;33:870.CrossRef Robinson CG, Patel AP, Bradley JD, DeWees T, Waqar SN, Morgensztern D, Baggstrom MQ, Govindan R, Bell JM, Guthrie TJ. Postoperative radiotherapy for pathologic N2 non–small-cell lung cancer treated with adjuvant chemotherapy: A review of the National Cancer Data Base. J Clin Oncol. 2015;33:870.CrossRef
6.
go back to reference Vansteenkiste JF, De Leyn PR, Deneffe GJ, Lerut TE, Demedts MG. Clinical prognostic factors in surgically treated stage IIIA-N2 non-small cell lung cancer: analysis of the literature. Lung Cancer. 1998;19:3–13.CrossRef Vansteenkiste JF, De Leyn PR, Deneffe GJ, Lerut TE, Demedts MG. Clinical prognostic factors in surgically treated stage IIIA-N2 non-small cell lung cancer: analysis of the literature. Lung Cancer. 1998;19:3–13.CrossRef
7.
go back to reference Betticher DC, Hsu SS, Tötsch M, Hansen E, Joss C, Von CB, Schmid RA, Pless M, Habicht J, Roth AD. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer. 2006;94:1099–106.CrossRef Betticher DC, Hsu SS, Tötsch M, Hansen E, Joss C, Von CB, Schmid RA, Pless M, Habicht J, Roth AD. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer. 2006;94:1099–106.CrossRef
8.
go back to reference PORT Meta-Analysis Trialists Group. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev. 2003;1. PORT Meta-Analysis Trialists Group. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev. 2003;1.
9.
go back to reference Evison M, Clive A, Castle L, Powell H, Thomas R, Buttery R, Masani V, Harden S, West D, Woolhouse I. Resectable clinical N2 non–small cell lung Cancer; what is the optimal treatment strategy? An update by the British Thoracic Society lung Cancer specialist advisory group. J Thorac Oncol. 2017;12:1434–41.CrossRef Evison M, Clive A, Castle L, Powell H, Thomas R, Buttery R, Masani V, Harden S, West D, Woolhouse I. Resectable clinical N2 non–small cell lung Cancer; what is the optimal treatment strategy? An update by the British Thoracic Society lung Cancer specialist advisory group. J Thorac Oncol. 2017;12:1434–41.CrossRef
10.
go back to reference Ramón Rami-Porta HA, William D. Travis, and Valerie W. Rusch: Lung. In: AJCC cancer staging manual. edn. Edited by MahuI B. Amin M, FCAP. AMERICAN JOINTCOMMITTEEON CANCER Executive Office: Springer International Publishing AG Switzerland. 2017;431–56. Ramón Rami-Porta HA, William D. Travis, and Valerie W. Rusch: Lung. In: AJCC cancer staging manual. edn. Edited by MahuI B. Amin M, FCAP. AMERICAN JOINTCOMMITTEEON CANCER Executive Office: Springer International Publishing AG Switzerland. 2017;431–56.
11.
go back to reference Asamura H, Chansky K, Crowley J, Goldstraw P, Rusch VW, Vansteenkiste JF, Watanabe H, Wu YL, Zielinski M, Ball D, Rami-Porta R. The International Association for the Study of Lung Cancer lung Cancer staging project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung Cancer. J Thorac Oncol. 2015;10:1675–84.CrossRef Asamura H, Chansky K, Crowley J, Goldstraw P, Rusch VW, Vansteenkiste JF, Watanabe H, Wu YL, Zielinski M, Ball D, Rami-Porta R. The International Association for the Study of Lung Cancer lung Cancer staging project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung Cancer. J Thorac Oncol. 2015;10:1675–84.CrossRef
12.
go back to reference Lin H, Chen Y, Shi A, Pandya KJ, Yu R, Yuan Y, Li J, Li H, Wang Y, Xia T, Feng L, Ma H, Geng J, Zhu G. Phase 3 randomized low-dose paclitaxel Chemoradiotherapy study for locally advanced non-small cell lung Cancer. Front Oncol. 2016;6:260.CrossRef Lin H, Chen Y, Shi A, Pandya KJ, Yu R, Yuan Y, Li J, Li H, Wang Y, Xia T, Feng L, Ma H, Geng J, Zhu G. Phase 3 randomized low-dose paclitaxel Chemoradiotherapy study for locally advanced non-small cell lung Cancer. Front Oncol. 2016;6:260.CrossRef
13.
go back to reference Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083–107.CrossRef Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083–107.CrossRef
14.
go back to reference Burdett S, Rydzewska L, Tierney J, Fisher D, Parmar M, Arriagada R, PORT Meta-analysis Trialists Group. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev. 2016;10;CD002142. Burdett S, Rydzewska L, Tierney J, Fisher D, Parmar M, Arriagada R, PORT Meta-analysis Trialists Group. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev. 2016;10;CD002142.
15.
go back to reference Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol. 2006;24:2998–3006.CrossRef Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol. 2006;24:2998–3006.CrossRef
16.
go back to reference Corso CD, Rutter CE, Wilson LD, Kim AW, Decker RH, Husain ZA. Re-evaluation of the role of postoperative radiotherapy and the impact of radiation dose for non–small-cell lung Cancer using the National Cancer Database. J Thorac Oncol. 2015;10:148–55.CrossRef Corso CD, Rutter CE, Wilson LD, Kim AW, Decker RH, Husain ZA. Re-evaluation of the role of postoperative radiotherapy and the impact of radiation dose for non–small-cell lung Cancer using the National Cancer Database. J Thorac Oncol. 2015;10:148–55.CrossRef
17.
go back to reference Le Péchoux C, Dunant A, Faivre-Finn C, Thomas P-A, Pourel N, Lerouge D, Edwards J, Van Schil P, Rami-Porta R, Dansin E, Nestle U, Fadel E, Zalcman G. Postoperative radiotherapy for pathologic N2 non–small-cell lung Cancer treated with adjuvant chemotherapy: need for randomized evidence. J Clin Oncol. 2015;33:2930–1.CrossRef Le Péchoux C, Dunant A, Faivre-Finn C, Thomas P-A, Pourel N, Lerouge D, Edwards J, Van Schil P, Rami-Porta R, Dansin E, Nestle U, Fadel E, Zalcman G. Postoperative radiotherapy for pathologic N2 non–small-cell lung Cancer treated with adjuvant chemotherapy: need for randomized evidence. J Clin Oncol. 2015;33:2930–1.CrossRef
18.
go back to reference Saji H, Tsuboi M, Yoshida K, Kato Y, Nomura M, Matsubayashi J, Nagao T, Kakihana M, Usuda J, Kajiwara N, Ohira T, Ikeda N. Prognostic impact of number of resected and involved lymph nodes at complete resection on survival in non-small cell lung cancer. J Thorac Oncol. 2011;6:1865–71.CrossRef Saji H, Tsuboi M, Yoshida K, Kato Y, Nomura M, Matsubayashi J, Nagao T, Kakihana M, Usuda J, Kajiwara N, Ohira T, Ikeda N. Prognostic impact of number of resected and involved lymph nodes at complete resection on survival in non-small cell lung cancer. J Thorac Oncol. 2011;6:1865–71.CrossRef
19.
go back to reference Wang J, Chen J, Chen X, Wang B, Li K, Bi J. Blood vessel invasion as a strong independent prognostic indicator in non-small cell lung cancer: a systematic review and meta-analysis. PLoS One. 2011;6:e28844.CrossRef Wang J, Chen J, Chen X, Wang B, Li K, Bi J. Blood vessel invasion as a strong independent prognostic indicator in non-small cell lung cancer: a systematic review and meta-analysis. PLoS One. 2011;6:e28844.CrossRef
20.
go back to reference Wang J, Wang B, Zhao W, Guo Y, Chen H, Chu H, Liang X, Bi J. Clinical significance and role of lymphatic vessel invasion as a major prognostic implication in non-small cell lung cancer: a meta-analysis. PLoS One. 2012;7:e52704.CrossRef Wang J, Wang B, Zhao W, Guo Y, Chen H, Chu H, Liang X, Bi J. Clinical significance and role of lymphatic vessel invasion as a major prognostic implication in non-small cell lung cancer: a meta-analysis. PLoS One. 2012;7:e52704.CrossRef
21.
go back to reference Kang DY, Lee S. Lymphatic vessel invasion and lymph node metastasis in patients with clinical stage I non-small cell lung cancer. Thorac Cardiovasc Surg. 2014;62:521–4.CrossRef Kang DY, Lee S. Lymphatic vessel invasion and lymph node metastasis in patients with clinical stage I non-small cell lung cancer. Thorac Cardiovasc Surg. 2014;62:521–4.CrossRef
22.
go back to reference Feng QF, Wang M, Wang LJ, Yang ZY, Zhang YG, Zhang DW, Yin WB. A study of postoperative radiotherapy in patients with non–small-cell lung cancer: a randomized trial. Int J Radiat Oncol Biol Phys. 2000;47:925–9.CrossRef Feng QF, Wang M, Wang LJ, Yang ZY, Zhang YG, Zhang DW, Yin WB. A study of postoperative radiotherapy in patients with non–small-cell lung cancer: a randomized trial. Int J Radiat Oncol Biol Phys. 2000;47:925–9.CrossRef
23.
go back to reference Hospes R. T4 surgery in Non-Small Cell Lung Cancer. University Medical Center Groningen. 2003. Hospes R. T4 surgery in Non-Small Cell Lung Cancer. University Medical Center Groningen. 2003.
24.
go back to reference Patel V, Shrager JB. Which patients with stage III non-small cell lung cancer should undergo surgical resection? Oncologist. 2005;10:335–44.CrossRef Patel V, Shrager JB. Which patients with stage III non-small cell lung cancer should undergo surgical resection? Oncologist. 2005;10:335–44.CrossRef
25.
go back to reference Mayer R, Smolle-Juettner F-M, Szolar D, Stuecklschweiger GF, Quehenberger F, Friehs G, Hackl A. Postoperative radiotherapy in radically resected non-small cell lung Cancer. Chest. 1997;112:954–9.CrossRef Mayer R, Smolle-Juettner F-M, Szolar D, Stuecklschweiger GF, Quehenberger F, Friehs G, Hackl A. Postoperative radiotherapy in radically resected non-small cell lung Cancer. Chest. 1997;112:954–9.CrossRef
26.
go back to reference Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. New Engl J Med. 2010;363:1693–703.CrossRef Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. New Engl J Med. 2010;363:1693–703.CrossRef
27.
go back to reference Pao W. New approaches to targeted therapy in lung cancer. Proc Am Thorac Soc. 2012;9:72–3.CrossRef Pao W. New approaches to targeted therapy in lung cancer. Proc Am Thorac Soc. 2012;9:72–3.CrossRef
28.
go back to reference Liao RG, Watanabe H, Meyerson M, Hammerman PS. Targeted therapy for squamous cell lung cancer. Lung Cancer Manag. 2012;1:293–300.CrossRef Liao RG, Watanabe H, Meyerson M, Hammerman PS. Targeted therapy for squamous cell lung cancer. Lung Cancer Manag. 2012;1:293–300.CrossRef
Metadata
Title
Postoperative chemoradiotherapy is superior to postoperative chemotherapy alone in squamous cell lung cancer patients with limited N2 lymph node metastasis
Authors
Liyu Su
Mingqiu Chen
Huiyan Su
Yaqing Dai
Shaoxing Chen
Jiancheng Li
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-6141-z

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine